Investors and Board
Our investors and board are invaluable partners in our mission to transform healthcare from an art to a science.
Board of Directors
James P. ‘Jim’ Bradley is Chairman of Apixio’s Board of Directors. He has extensive executive and board experience in the healthcare industry and was Chief Information Officer at UnitedHealthcare, a senior executive at McKesson Corporation, and led operations for the Northern half of Aetna’s managed care plans. He also founded Abaton.com Inc, a developer of web-based physician connectivity services and applications, and led it to a successful exit via sale to McKesson. He currently serves as Chairman of the Board of Novu LLC and Wellpartner Inc.
Jim has lectured on health policy and health information technology at Harvard, Wharton and other leading universities. He has served on the boards of several non-profits, including NCQA, the Health Data Consortium, and the Research Foundation of the American Society of Health System Pharmacy. Jim holds a MBA from Washington University, St. Louis, MO, and received his BS and MS degrees from the University of Illinois.
Darren Schulte, MD, has over eleven years of industry experience in healthcare analytics and technology. Darren served as the Chief Medical Officer and President of Apixio prior to being appointed CEO in 2014. Before joining Apixio, Darren served in executive leadership roles at Alere, Anvita Health, and Resolution Health. Darren co-developed 25 clinical measures endorsed by the National Quality Forum to assess ambulatory care quality measurement using electronic data. Darren is a nationally recognized speaker on the topics of healthcare analytics and quality improvement. Darren received his BS degree from Berkeley, MPP degree from Harvard, and MD from Stanford. He trained in Internal Medicine at UCSF, and is co-author of one US patent.
Shahin Hedayat has a passion for high tech entrepreneurship addressing complex problems through collective human ingenuity. Shahin has been an entrepreneur for 18 years starting companies with the aim of creating impactful social and economic benefits for all stakeholders. Shahin co-founded 4 companies, Centillium Communication, Beceem Communication, Enverv, and Apixio, at which he has served various roles as President, CEO, Chairman and Board Member. Centillium, Beceem and Enverv reached maturation through IPO and acquisitions generating over $4 billion of total shareholder value. Prior to 1997, Shahin held technical and managerial roles at Cirrus Logic for 11 years where he became VP of Engineering of a product line that generated annual revenue of $90 million. Shahin holds BS and MS degrees from the University of Michigan, and is co-author of 9 US patents.
Petro Estakhri co-founded and is CEO for Avalanche Technology. Prior to Avalanche, Petro served as the CTO of Lexar Media, a pioneer in flash memory technology, which he founded in 1996. Lexar Media grew to be the 55th largest company in Silicon Valley prior to its acquisition by Micron Technology, Inc. in 2006. Prior to Lexar Media, Petro developed the primary micro-controllers and co-founded the mass storage memory group at Cirrus Logic. Petro has also held positions at IBM and National Semiconductor. Petro has served as a member of many Boards, including Lexar Media and Silicon Stor, a company that Petro co-founded in 2002. Petro holds a BS and an MS in electrical and computer engineering from UC Davis. Petro is a co-author of over 95 patents related to magnetic media, flash storage controller and systems architecture.
Casey focuses on investments in Healthcare and Software & Technology companies. Prior to joining SSM, he worked at Petra Capital Partners and Donaldson, Lufkin & Jenrette Securities Corporation. Casey received his bachelor’s degree in History from the Virginia Military Institute and an MBA from the Harvard Business School.
Joel Portice is the Chief Executive Officer of Intermedix. He is responsible for the overall business and strategic direction of the enterprise. He has more than 20 years of experience in healthcare data analytics in the public and private healthcare industries. Prior to joining Intermedix, Joel held several executive management positions; he was the President of Verisk Health and led it to unprecedented growth through innovation and increased market share, was the co-founder and Chief Operating Officer of Enclarity, which was acquired by LexisNexis, and, most recently, he served as President of Government Solutions and Corporate Strategy at HMS Holdings Corp. Joel earned his Bachelor’s degree in Political Science from the University of South Dakota and holds a Master’s degree in Management from Hamline University. He was appointed Trustee Emeritus of Hamline University in 2012 and received the Alumni Achievement Award for Professional Achievement from USD in 2013.
Eric A. Shuey serves as a Senior Advisor to Bain Capital Ventures and has more than twenty-five years of corporate finance and private equity investing experience. He currently serves on the board of several leading health care services and IT companies including: Encore Rehabilitation Services, LLC; MedeAnalytics; Partners Surgical; Remedy Partners; and Sound Physicians, Inc. Eric previously served as the Chief Financial Officer of Liberty Dialysis Holdings, Inc. Eric was part of a management team that grew Liberty Dialysis to annual revenue in excess of $1 billion before being acquired by Fresenius Medical Care AG in early 2012 for over $2.3 billion. Eric earned an MBA from the Wharton School of Business, where he was a Palmer Scholar. In addition, he has completed the coursework for a Ph.D. in Management at the Wharton School and earned his BA from California State University, Fullerton with highest honors.
SSM Partners draw upon over 20 years of experience and success building companies to provide the best possible support to our partners. Our expertise, networks and resources create an advantage for our partners throughout the company-building process.
Founded in 1984, Bain Capital has become one of the world’s leading private multi-asset alternative investment firms by constantly looking for new and different ways to create value.